The viral Myb (v-Myb) This suggests a novel link between Myb, a signal transduction pathway, co-operativity with C/EBP and a point mutation in the myb oncogene.
INTRODUCTION
The v-myb oncogene and its cellular progenitor c-myb both encode transcription factors that are implicated in the switch between growth and differentiation of hematopoietic cells (reviewed in (1-4) ). The c-Myb protein consists of a N-terminal DNA-binding domain (DBD), a central transactivation domain (TAD) and a C-terminal negative regulatory domain (NRD). The DBD of c-Myb is comprised of the three imperfect repeats: R 1 , R 2 and R 3 , each related to the helix-turn-helix motif (5-7). R 1 is deleted in v-Myb and the R 2 and R 3 repeats are sufficient for sequence-specific DNA binding (hereafter termed mDBD, minimal DNA-binding domain). This prototype Myb mDBD is highly conserved throughout evolution in the animal and plant kingdoms (8) .
A large body of evidence supports a central role for c-Myb in regulating cell growth and differentiation (reviewed in (4)), in particular in hematopoietic progenitor cells of different lineages (9) (10) (11) (12) (13) (14) (15) . This function is consistent with phenotypes observed in mice with a c-myb null mutation and in homozygous null c-Myb/Rag1 chimeric mice (11, 13) . The c-Myb protein has also been reported to be expressed in a variety of tissues in developing embryos and/or in adult tissues such as tooth buds, retina and epithelium of the gastrointestinal and repiratory tracts and Page 7 assay and by fluorescence quenching (43) to ensure equal amounts of each protein in the experimental protocol.
The mDBD domain contains six highly conserved tryptophan residues, which makes the protein suitable for conformational analysis by fluorescence emission spectrum analysis.
Spectroscopic analyses were performed as described (38, 43) .
In vitro phosphorylation of mDBD proteins
For phosphorylation site mapping experiments, recombinant wild type and mutant mDBD c-Myb proteins (8 pmol) were incubated in PKA buffer (20 mM HEPES pH 7.9, 60 mM KCl, 5 mM MgAc, 1 mM dithiothreitol), 5mCi (3.3 pmol) [g- 32 MS analysis. Phosphoaminoacid analysis of 32 P-phosphorylated wild-type and mutant S146A mDBD domains was performed as described (44) . A MALDI-TOF Mass spectrometer (Voyager-RP DE, Applied Biosystems) was employed to measure the molecular mass of PKAphosphorylated wild-type and mutant mDBD domains. All experiments were carried out with the mass spectrometer in the linear positive ion mode. The total acceleration voltage was 25 kV. The voltage on the first grid and the delay time between ion production and extraction were adapted to the mass of the different samples. 100 single scans were accumulated for each spectrum. The matrix, 3,5-dimethoxy-4-hydroxycinnamic acid (Sigma, D-7927), was dissolved at a concentration of 15 mg/ml in a mixture of 1:1 acetonitrile/0,1% aqueous TFA. 0,5 µl of sample and 1,5 µl of matrix were mixed together on the sample plate and air-dried. All data were calibrated using an external calibration standard mixture (Applied Biosystems). is a triple mutant variant of the GG MRE oligo. All oligos were end-labelled and purified through a G-25 spin column. Cold double-stranded oligos for competition were similarly annealed.
Variant MRE oligos were labelled to the same specific activity (47) and purified through a G-25 spin column.
Cell Lines
The c-Myb expressing erythroid cell line HD3, quail QT6 fibroblasts, and the HD11 cell line expressing v-myc have been described (49) . All cells were grown in Dulbecco's modified Eagle medium supplemented with 8% fetal bovine serum, 2% heat-inactivated chicken serum, 15 mM HEPES, penicillin, and streptomycin. Cells were maintained in 5% CO 2 atmosphere at 39 o C.
Immunoprecipitation and Western analysis
A synthetic peptide coding for the human/chicken c-Myb internal twelve amino acids (C+LVQKYGPKRWSV), in which the second last serine was phosphorylated, was conjugated and used for immunization using the antibodies service of Eurogentec Bel S.A.
For immunoprecipitation 6 x 10 6 QT6 cells were seeded 5 hrs before transfection in 10 ml tissue culture medium. Cells were subsequently transfected with 10 mg of expression vectors as indicated, using a calcium phosphate coprecipitation technique (50) . Cells were harvested [16] [17] [18] hr post transfection. For HD3 immunoprecipitation 2x10 7 cells were used. Cell lysates were prepared in 0,3 ml lysis buffer (20mM Tris pH 7.5, 150 mM NaCl, 1mM EDTA pH8, 10%
glycerol, 0,8% NP40, 0.1% Deoxycholate, 1mM DTT, 1 mM PMSF, 10 mg/ml of each aprotinin, pepstatin and leupeptin).
Expressed proteins were precipitated with a pre-immune rabbit serum, a Myb specific rabbit immune serum and a Myb PKA-site specific rabbit immune serum as indicated for 2 hrs at 4 °C. A-Sepharose (Pharmacia) was added, incubated for 1 hr, and washed extensively with lysis buffer. Immunoprecipitates were separated by 10% SDS-PAGE, and transferred to PVDF membranes (Millipore). Precipitated proteins were revealed with a mouse monoclone antibody directed against c-Myb (MYB2-7.77; ATCC), appropriate peroxidase conjugated second antibodies and subsequently revealed using a chemiluminescence kit (ECL, Amersham).
Transient Transfections, Reporter Assay, and Resident Gene Activation Assay
Plasmids used for transfections were purified twice on CsCl gradients. QT6 and HD11 cells were transfected using DEAE-dextran as described previously (51) . To monitor reporter gene activation, cells were harvested after 24 hr, whole cell lysates were prepared, and luciferase activity was determined as previously described (51, 52) . Activation of endogenous genes was determined as previously described ((53, 54) .
RESULTS

A PKA phosphorylation site in the c-Myb mDBD (R 2 R 3 )
Two putative PKA sites were identified in c-Myb by a Prosite motif search (55), namely S116 (KRWSV) and S146 (KKTSW). Both residues reside in the R 2 R 3 minimal DNA-binding domain (mDBD) and conformed well to the PKA consensus motif RRXS/TY (45) . An alignment of vertebrate Myb proteins (Fig. 1a) shows that both sites are highly conserved. Mapping of these two sites onto the published NMR structure of mouse mDBD (7) and the recent crystal structure (37), showed that they are both on the surface of the protein and hence should be accessible for interaction with other proteins (Fig. 1b) . Note the close proximity of S116 to the DNA sugarphosphate backbone in the model.
A Myb fragment, consisting of the N-terminus and all three repeats (amino acids has been shown to be a phosphorylation target of PKA (56) . Pilot biochemical experiments with recombinant c-Myb mDBD domain corresponding to the AMV-myb version (amino acids showed that this domain was also readily phosphorylated in vitro by PKA catalytic subunit (data not shown). In order to map the PKA phosphorylation site(s), mutant mDBD domains carrying the mutations S116A, S146A and the double mutant S116A/S146A were expressed in E.coli and purified by affinity and ion-exchange chromatography (5). To exclude indirect structural effects of the mutations introduced, the overall conformations of the mutant mDBD proteins were compared with wild type mDBD by fluoresence quenching spectroscopy as described (38) . We did not detect any gross structural changes as a consequence of introducing mutations at the S116 and S146 positions of mDBD (data not shown).
Wild type and mutant mDBD domains were used in phosphorylation site mapping experiments with purified PKA C a catalytic subunit and [g-32 P]ATP. The results in Fig. 2a showed that the S116A mutation (lanes 3, 5) completely abolished the mDBD phosphorylation (lane 2), whereas the S146A mutation (lane 4) had no effect. An SDS-PAGE analysis of the mDBD proteins demonstrated equal amounts of protein in the phosphorylation reactions (Fig 2a, lower panel). Phosphoaminoacid analysis of wild-type and S146A mutant mDBD domains confirmed phosphorylation on serine residues only ( Fig. 2b ). Mass spectrometry analysis showed the addition of one phosphate group in wild-type and S146A mDBD, but not in S116A mDBD (Fig. 2c ). In conclusion, of the three serines present in c-Myb mDBD (S116, S146 and S187), only S116 is a PKA target site.
The Michaelis constant (Km) of mDBD as a substrate for PKA was determined using purified bacterially expressed mDBD, PKA C a and [g-32 P]ATP as described in the Materials and Methods (Fig. 3) . The Km was calculated to be 10 µM. This value is in good accordance with other well-defined substrates for PKA. The determination of S116 in c-Myb as a high affinity site for PKA is consistent with conclusions by Ramsay and co-workers, who reported that S116 in Cterminally truncated recombinant Myb proteins was phosphorylated by PKA in vitro (33) .
The oncogenic V117D mutation in AMV-Myb abrogates PKA mediated phosphorylation
In AMV v-Myb, the V117D point mutation located next to the S116 residue abolishes the PKA recognition motif (as defined by an extended consensus, Fig. 1a ). To examine whether the V117D mutation potentially interferes with S116 phosphorylation, experiments were performed with recombinant wild type and mutant mDBD proteins and PKA C a as shown in Figure 4 . In contrast to wild type mDBD, the AMV mDBD (R 2 R 3 carrying the three AMV mutations I91N, L106H, and V117D) (38) was not phosphorylated by PKA (Fig. 4 , lanes 2 and 3). Introduction of the single AMV-Myb point mutation V117D in c-Myb also abrogated the PKA phosphorylation of the domain (lane 4). In the reciprocal experiment, back-mutation of the D117 to V117 restored PKA phosphorylation of the AMV-Myb mDBD (Fig. 4 lane 7) . We therefore conclude that cMyb but not v-Myb can be phosphorylated at S116.
Phosphorylation of S116 affects the stability of c-Myb / DNA interaction
In the NMR and crystal structures of c-Myb mDBD, the S116 residue is in close proximity to the sugar-phosphate backbone of the DNA helix (see Fig. 1b and (7, 37)). A predicted consequence of phosphorylation would therefore be interference with DNA binding due
to electrostatic repulsion. We tested this idea by phosphorylating wild type mDBD in vitro with PKA C a , and assaying DNA binding on EMSA gels using the mim-1A binding site (MRE) (46) as DNA probe. Quantitative phosphorylation was consistently >75%, as calculated by 32 P incorporation and mass spectrometry. As shown in Fig. 5a , the DNA binding activity of phosphomDBD was reduced (lanes 1 and 3) compared to non-phosphorylated mDBD (lanes 2 and 4).
Phosphorylated mDBD migrated also slightly faster in the gel than non-phosphorylated mDBD.
Phosphorylation of mDBD diminished DNA-binding, but did not totally abolish complex formation. We confirmed that phospho-mDBD was able to bind to the cognate MRE sequence by running EMSA reactions with [g-32 P]ATP-labeled mDBD protein and unlabeled DNA oligo ( We have previously shown that subtle differences in DNA binding for c-Myb proteins may be detected by analysis of decay of protein-DNA complexes in EMSA ("decay-EMSA") (38, 47, 48) . After the formation of a protein-DNA complex, a large excess of unlabelled specific DNA oligo is added, and the time course of complex dissociation is followed by analyzing the remaining complexes at different time points by EMSA. Decay-EMSA was performed on wild type mDBD, a S116D mutant (a phosphorylation mimic) and an in vitro phosphorylated mDBD proteins (n=4). A typical experiment is shown in figure 5c . Note that threefold more phosphomDBD protein than wild type or S116D mutant mDBD was loaded onto the gel in order to visualize the protein/DNA complexes. PKA-phosphorylation of the mDBD protein led to a dramatic increase in the dissociation rate of the protein/DNA complex (Fig. 5c , lanes 12-16) compared to the non-phosphorylated mDBD (lanes 2-6). The dissociation rate of the mDBD S116D mutant from the complex was also increased compared to wild type mDBD (compare lanes 7-11). The protein/DNA dissociation rates were estimated to be approximately >20 min, 2-5 min and <1 min for wild type, S116D and phospho-S116 mDBD proteins, respectively (n=4).
Note that the S116D mutation in mDBD did not fully mimic PKA-phosphorylated mDBD with regard to DNA binding properties. An alternative mutant, S116E mDBD, exhibited similar properties as the S116D mutant. The neutral S116A mDBD mutant exibited a similar decay rate as wild type mDBD (n=2, data not shown), thus excluding a general effect of mutations at S116.
PKA phosphorylation differentially affects c-Myb binding to various MRE sites
In previous studies, we have developed an EMSA system for evaluating the selectivity of 4) was similar to the results obtained with the MRE oligo (Fig. 5) . Binding to the GT and TG oligos was almost completely abrogated (lanes 5-8 and 9-12, respectively).
Phosphoimager analysis revealed that reduction of DNA-binding was approximately 60%, 89%
and 88% for the GG, GT and TG oligos, respectively (n=4). The TT oligo (lanes 13-16), which is not bound by c-Myb, was included as a negative control.
DNA bound Myb is barely accessible to PKA phosphorylation
We have previously reported that the R 2 repeat (in which S116 resides) undergoes a disorder-to-order transition upon binding to DNA (43, 57, 58) . Experiments were therefore performed to investigate whether this transition could affect the accessibility of S116 in a free mDBD versus in an mDBD-DNA complex. Phosphorylation reactions with PKA C a subunit were performed on free mDBD protein, on mDBD pre-incubated with a specific DNA oligo (MRE) or mDBD preincubated with an unspecific DNA oligo (NSO). The pre-formation of a mDBD/MRE complex severely reduced the phosphorylation of mDBD compared to free mDBD protein (Fig.   6b , lanes 7-12 compared with lanes 1-6). In contrast, preincubation of mDBD with a non-specific oligo (NSO) barely affected PKA-mediated mDBD phosphorylation (Fig. 6b, lanes 13-18) . This demonstrates that sequence specific DNA-binding severely reduces the accessibility of the S116
site. This could be due to direct shielding by DNA or be a consequence of a DNA-induced conformational change in R 2 . Irrespective of the mechanism, the results suggest that S116 can be present in an "open" or "closed" conformation, being accessible and efficiently modified in the free protein, but changing into a site with poor accessibility for the kinase in the protein-DNA complex.
c-Myb, but not AMV v-Myb, is phosphorylated at S116 in intact cells
An important question to ask was whether a steady-state pool of S116-phosphorylated cMyb existed in cells. Antibodies against an S116-phosphorylated c-Myb were generated to elucidate this possibility. As shown in Figure 7A , the antiserum recognizes PKA-phosphorylated mDBD, but not non-phosphorylated protein ( The antibody was subsequently used to determine whether endogenous c-Myb is phosphorylated at S116 in vivo. HD3 erythroblasts were chosen as they express high levels of cMyb. As shown in Figure 7B , the phospho-c-Myb (S116) 20) . We conclude that c-Myb can be phosphorylated at S116 and that the V117D mutation present in AMV v-Myb abolishes this phosphorylation site.
Introduction of charge in S116 affects resident Myb-target gene expression
In effector-reporter experiments we failed to observe significant differences between wild type c-Myb, S116A, and phospho-mimicking S116D, S116E mutations (data not shown).
However Ramsay and coworkers located two PKA phosphorylation sites in c-Myb by phosphopeptide mapping of a C-terminal truncated c-Myb protein revealing S8 and S116 as substrates for PKA in vitro (33) . However, in contrast to our observations, no functional effects of the phosphorylation of S116 were reported. Our data show that phosphorylation of S116 has biochemical and functional consequences. Phosphorylation of S116 destabilizes Myb binding to DNA and a S116D phosphorylation mimic protein failed to activate the resident mim-1 gene.
Whether this effect is due to destabilization of DNA-interaction, or loss of co-operativity with C/EBP is currently difficult to resolve. However, we can infer that the loss-of-function of AMV v-Myb to cooperate with C/EBP, is at least in part due to the mutation at V117D. Backmutation of D117V in AMV v-Myb regained some of the functional C/EBP/Myb-dependent gene activation, while constitutive activation of GBX2 was severely diminished (40) . This back mutation also changed the transformed phenotype towards the granulocytic lineage and displayed reduced leukemogenicity in retroviral transformation studies (39) . However, the reciprocal single mutation V117D in wt Myb setting was not sufficient to abrogate C/EBP collaboration entirely or to induce constitutive GBX2 activation (E. K.-L. and A. L., unpublished observations). This is in keeping with the recent structural data, where I91 and L106 in wt c-Myb directly interacted with C/EBPb, whereas V117 indirectly affects C/EBP interaction (37). Accordingly, the point mutation at V117D required the other R 2 v-Myb mutations to achieve the complete v-Myb phenotype. Taken together, these data suggest that the phospohorylation at S116 or abrogation of this phosphoacceptor site by the AMV v-Myb specific mutation has multiple effects on Myb function, including a direct influence on the interaction of the DBD of Myb with its co-factors.
Our data show that phosphorylation at S116 leads to decreased binding of Myb to MREs.
The destabilization of the Myb-DNA complex upon PKA phosphorylation could be a consequence of electrostatic repulsion since the S116 residue is in close proximity to the DNA sugar-phosphate backbone (Fig. 1c) . However, additional effects of the introduced phosphate may be postulated since a substitution of S116 with aspartic acid or glutamic acid to mimic a negative charge in this position showed a less profound inhibition of DNA binding compared to A) Recombinant wild type (wt) and mutant mDBD (S116A, S146A and S116A/S146A) domains S116A, S146A amd S116A/S146A mDBD proteins, respectively. B) Phosphoaminoacid analysis of 32 P-radiolabeled wt and S146A mDBD proteins. Outlines of the ninhydrin staining of unlabeled phosphoserine (P-Ser), phosphothreonine (P-Thr) and phosphotyrosine (P-Thr) standards are indicated. C) Molecular mass measurements of wt, S116A and S146A mDBD proteins incubated in the absence or presence of PKA-C a . are given in Daltons. Molecular masses calculated from the primary sequence (calculated), the increase in molecular mass in the presence of PKA (D) and the calculated mass increase of one phosphate group addition are also shown. Samples from the lysates were also loaded as expression control. Lysate IP p r e -i m m u n e a n t i -M y b a n t i -M y b ( S 1 1 6 P ) p r e -i m m u n e a n t i -M y b a n t i -M y b ( S 1 1 6 P ) p r e -i m m u n e a n t i -M y b a n t i -M y b ( S 1 1 6 P ) p r e -i m m u n e a n t i -M y b a n t i -M y b ( S 1 1 6 P ) p r e -i m m u n e a n t i -M y b a n t i -M y b ( S 1 1 6 P ) 
